Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11786487B2 · kind B2 · utility
2Cited by
65References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 19, 2021 |
| Grant date | Oct 17, 2023 |
| Priority date | — |
| Expiry date | Jan 9, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.